Patient centric drug product design in modern drug delivery as an opportunity to increase safety and effectiveness

References

• Marcum ZA, Pugh MJV, Amuan ME, et al. Prevalence of potentially unplanned hospitalizations caused by therapeutic failures and adverse drug withdrawal events among older veterans. J Gerontol A Biol Sci Med Sci. 2012;67(8):867–874.
   PubMed Web of Science ®Google Scholar
• Lin C-W, Wen YX-W, Chen L_K, et al. Potentially high-risk medication categories and unplanned hospitalizations: a case-time-control study. Sci Rep. 2017;7:41035.
   PubMed Web of Science ®Google Scholar
• Probst LA, Welch TR. Pediatric drug formulations – unintended consequences of legislation. N Engl J Med. 2017;376(8):795–796.
   PubMed Web of Science ®Google Scholar
• Stegemann S. Drug administration via enteral tubing: an unresolved but increasing challenge. Expert Opin Drug Deliv. 2015;12(2):159–161.
   PubMed Web of Science ®Google Scholar
• Eliott RA. Problems with medication use in the elderly: an Australian perspective. J Pharm Pract Res. 2006;36(1):58–66.
   Google Scholar
• Noteboom K, Beers E, van Riet-Nales DA, et al. Practical problems with medication use that older people experience: a qualitative study. J Am Geriatr Soc. 2014;62:2339–2344.
   PubMed Web of Science ®Google Scholar
• Beckman AGK, Parker MG, Thorslund M. Can elderly people take their medicines? Patient Educ Couns. 2005;59:186–191.
   PubMed Web of Science ®Google Scholar
• Yu LX. Pharmaceutical quality by design: product and process development, understanding, and control. Pharm Res. 2008;25(4):781–791.
   PubMed Web of Science ®Google Scholar
• FDA (2009) Q8 Pharmaceutical Development Revision 1. Acessed on September 30, 2017. (https://www.fda.gov/OHRMS/DOCKETS/98fr/07d-0493-gdl0001.pdf)
   Google Scholar
• Page S, Coupe A, Barrett A. An industrial perspective on the design and development of medicines for older patients. Int J Pharm. 2016;512:352–354.
   PubMedGoogle Scholar
• ICH Q8 R2 Guideline (2009) Pharmaceutical Development. Acessed on September 30, 2017. (https://www.ich.org/fileadmin/Public_Web_Site/ICH_Products/Guidelines/Quality/Q8_R1/Step4/Q8_R2_Guideline.pdf)
   Google Scholar
• FDA (2016) Applying human factors and usability engineering to optimize medical device design. Draft Guidance for industry and Food and Drug Administration Staff. Acessed on September 30, 2017. (http://www.fda.gov/downloads/MedicalDevices/…/UCM259760.pdf9
   Google Scholar
• FDA (2016) Use of real-world evidence to support regulatory decision-making for medical devices. Draft Guidance. Acessed on September 30, 2017. (https://www.fda.gov/downloads/medicaldevices/deviceregulationandguidance/guidancedocuments/ucm513027.pdf)
   Google Scholar
• FDA (2016) Guidance for Industry. Safety considerations for product design to minimize medication errors. Acessed on September 30, 2017. (http://www.fda.gov/downloads/drugs/guidancecomplianceregulatoryinformation/guidances/ucm331810.pdf)
   Google Scholar
• EMA (2015) Good practice guide on risk minimisation and prevention of medication errors EMA/606103/2014. Acessed on September 30, 2017. http://www.ema.europa.eu/docs/en_GB/document_library/Regulatory_and_procedural_guideline/2015/11/WC500196981.pdf
   Google Scholar
• EMA (2014) Guideline on good pharmacovigilance practice (GVP) Module VI: -Management and reporting of adverse reactions to medicinal products (Rev 1). Acessed on September 30, 2017. (http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2014/09/WC500172402.pdf)
   Google Scholar
• EMA (2006) Reflection Paper: formulations of choice for the pediatric population. EMA/CHMP//PEG/194810/2005. Acessed on September 30, 2017. (http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2009/09/WC500003782.pdf)
   Google Scholar
• EMA (2013) Guideline on the pharmaceutical development of medicines for pediatric use. EMA/CHMP/QWP/805880/2012 Rev. 2. Acessed on September 30, 2017. (http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2013/07/WC500147002.pdf)
   Google Scholar
• EMA (2017) Reflection paper on the pharmaceutical development of medicines for use in the older population. Acessed on September 30, 2017. http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2017/08/WC500232782.pdf
   Google Scholar
• Schenone M, Dancik V, Wagner BK, et al. Target identification and mechanism of action in chemical biology and drug discovery. Nat Chem Biol. 2013;9(4):232–240.
   PubMed Web of Science ®Google Scholar
• Landis MS, Bhattachar S, Yazdanian M, et al. Commentary: why pharmaceutical scientists in early drug discovery are critical for influencing the design and selection of optimal drug candidates. AAPS PharmSciTech. 2018;19(1):1–10.
   PubMed Web of Science ®Google Scholar
• Nobili A, Marengoni A, Tettamanti M, et al. Association between clusters of diseases and polypharmacy in hospitalized elderly patients: results from the REPOSI study. Eur J Intern Med. 2011;22(6):597–602.
   PubMed Web of Science ®Google Scholar
• Hanson MA, Cooper C, Aihie Sayer A, et al. Developmental aspects of a life course approach to healthy aging. J Physiol. 2016;594(98):2147–2160.
   PubMedGoogle Scholar
• Turnheim K. Pharmacokinetic dosage guidelines for elderly subjects. Expert Opin Metb Toxicol. 2005;1(1):33–48.
   PubMedGoogle Scholar
• Shah RR. Drug development and use in the elderly: search for the right dose and dosing regimen. Br J Clin Pharmacol. 2004;58(5):452–469.
   PubMed Web of Science ®Google Scholar
• Cusack BJ. Pharmacokinetics in older persons. Am J Geriat Pharmacother. 2004;2(4):274–302.
   PubMedGoogle Scholar
• McLean AJ, Le Couteur DG. Aging biology and geriatric clinical pharmacology. Pharmacol Rev. 2004;56:163–184.
   PubMed Web of Science ®Google Scholar
• König M, Gollasch M, Demuth I, et al. Prevalence of impaired kidney function in the German elderly: results from the Berlin Aging Study (BASE). Gerontol. 2017;63:201–209.
   PubMed Web of Science ®Google Scholar
• Björkman IK, Fastbom J, Schmidt IK, et al. Drug-drug interactions in the elderly. Ann Pharmacother. 2002;36:1675–1681.
   PubMed Web of Science ®Google Scholar
• Boobis A, Watelet J-B, Whomsley R, et al. Drug Interactions. Drug Metab Rev. 2009;41(3):486–527.
   PubMed Web of Science ®Google Scholar
• Cerreta F, Ankri J, Bowen D, et al. Baseline frailty evaluation in drug development. J Frailty Aging. 2016;5(3):139–140.
   PubMed Web of Science ®Google Scholar
• EMA (2018) Reflection paper on physical frailty: instruments for baseline characterization of older populations in clinical trials. EMA/CHMP/778709/2015. Acessed on September 30, 2017. (http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2018/02/WC500244285.pdf)
   Google Scholar
• Inouye SK, Studenski S, Tinetti ME, et al. Geriatric syndromes: clinical, reasearch and policy implications of a core geriatric concept. J Am Geriatr Soc. 2007 May;55(5):780–791.
   PubMed Web of Science ®Google Scholar
• Reddy P, Martinez-Martin P, Brown RG, et al. Perceptions of symptoms and expectations of advanced therapy for Parkinson’s disease: preliminary report of a Patient-Reported Outcome tool for Advanced Parkinson’s disease (PRO-APD). Health Qual Life Outcomes. 2014;12:11.
   PubMed Web of Science ®Google Scholar
• Manning LK, Carr DC, Kail BL. Do higher levels of resilience buffer the deleterious impact of chronic illness on disability in later life? Gerontologist. 2016;56(3):514–524.
   PubMed Web of Science ®Google Scholar
• Puts MTE, Shekary N, Widdershoven G. What does quality of life mean to older frail and non-frail community-dwelling adults in the Netherlands? Qual Life Res. 2007;16:263–277.
   PubMed Web of Science ®Google Scholar
• Jackson CA, Jones M, Tooth L, et al. Multimorbidity patterns are differentially associated with functional ability and decline in a longitudinal cohort of older women. Age Ageing. 2015;44:810–816.
   PubMed Web of Science ®Google Scholar
• Poblador-Plou B, van den Akker M, Vos R, et al. Similar multimorbidity patterns in primary care patients from two European regions: results of a factor analysis. PLoS ONE. 2014;9(6):100375.
   PubMed Web of Science ®Google Scholar
• Prados-Torres A, Poblador-Plou B, Calderon-Larranaga A, et al. Multimorbidity patterns in primary care: interactions among chronic diseases using factor analysis. PLoS ONE. 2012;7(2):e32190.
   PubMed Web of Science ®Google Scholar
• Clerencia-Sierra M, Calderon-Larranaga A, Martinez-Velilla N, et al. Multimorbidity patterns in hospitalized older patients: association among chronic diseases and geriatric syndromes. PLoS ONE. 2015;10(7):e0132909.
   PubMed Web of Science ®Google Scholar
• Vetrano DL, Calderón-Larrañaga A, Marengoni A, et al. An international perspective on chronic multimorbidity: approaching the elephant in the room. J Gerontol A Biol Sci Med Sci. 2017. DOI:10.1093/gerona/glx178
   PubMed Web of Science ®Google Scholar
• Collins FS, Hamburg MA. First FDA authorization for next generation sequencer. N Engl J Med. 2013;369(25):2369–2371.
   PubMed Web of Science ®Google Scholar
• Dolgin E. Massive schizophrenia genomics study offers new drug directions. Nature Rev Drug Discovery. 2014;13:641–643.
   PubMed Web of Science ®Google Scholar
• Giacomini KM, Yee SW, Mushiroda T, et al. Genome-wide association studies of drug response and toxicity: an opportunity for genome medicine. Nature Rev Srug Discovery. 2017;16:70–73.
   Web of Science ®Google Scholar
• Tricoli A, Nasiri N, De S. Wearable and miniatirized sensor technologies for personalized and preventive medicine. Adv Funct Mater. 2017;27:1605271.
   Web of Science ®Google Scholar
• Auffray C, Charron D, Hood L. Predictive, preventive, personalized and participatory medicine: back to the future. Genome Med. 2010;2:57.
   PubMed Web of Science ®Google Scholar
• Hamburg MA, Collins FS. The path to personalized medicine. N Engl J Med. 2010;363:301–304.
   PubMed Web of Science ®Google Scholar
• Dellhag B, Bjelle A. A 5 year followup on hand function and activities of daily living in rheumatoid arthritis patients. Arthritis Care Res. 1999;12(1):33–41.
   PubMed Web of Science ®Google Scholar
• The Accord Study Group. Effects on medical therapies on retinopathy progression in type 2 diabetes. N Engl J Med. 2010;363(3):233–244.
   PubMed Web of Science ®Google Scholar
• Stuck AE, Walthert JM, Niolaus T, et al. Risk factors for functional status decline in community-living elderly people: a systematic literature review. Soc Sci Med. 1999;48:445–469.
   PubMed Web of Science ®Google Scholar
• Fried LP, Bandeen-Roche K, Kasper JD, et al. Association of co-morbidity with disability in older woman: the woman’s health and aging study. J Clin Epidemiol. 1999;52:27–37.
   PubMed Web of Science ®Google Scholar
• Stenholm S, Westerlund H, Head J, et al. Comorbidity and functional trajectories from midlife to old age: the health and retirement study. J Gerontol A Biol Sci Med Sci. 2015;70(3):330–336.
   Web of Science ®Google Scholar
• Lee ER, Kawas CH, Gibbs L, et al. Prevalence of frailty and factors associated with frailty in individuals aged 90 and older: the 90+ study. J Am Geriatr Soc. 2016;64(11):2257–2262.
   PubMed Web of Science ®Google Scholar
• Fried LP, Ferrucci L, Darer J, et al. Untangling the concepts of disability, frailty, and comorbidity: implications for improved targeting and care. J Gerontol Med Sci. 2004;59(3):255–263.
   PubMed Web of Science ®Google Scholar
• Zink A, Braun J, Listing J, et al. Disability and handicap in rheumatoid arthritis and ankylosing spondylitis - results from the German rheumatological database. German collaborative arthritis centers. J Rheumatol. 2010;27(3):613–622.
   Google Scholar
• Gregg EW, Brown A. Cognitive and physical disabilities and aging-related complications of diabetes. Clin Diabet. 2003;21(3):113–118.
   Google Scholar
• Boyd KJ, Murray SA, Kendall M, et al. Living with advanced heart failure: a prospective, community based study of patients and their carers. Eur J Heart Failure. 2004;6(5):585–591.
   PubMed Web of Science ®Google Scholar
• Verbrugge LM, Brown DC, Zajacova A. Disability rises gradually for a cohort of older Americans. J Gerontol B Psychol Sci Soc Sci. 2017;72(1):151–161.
   PubMed Web of Science ®Google Scholar
• Carbone F, Holvoet L, Vandenberghe A, et al. Functional dyspepsia: outcome of focus groups for the development of a questionnaire for symptom assessment in patients suffering from postprandial distress syndrome (PDS). Neurogastroentero Motil. 2014;26(9):1266–1274.
   PubMed Web of Science ®Google Scholar
• Gelb DJ, Oliver E, Gilman S. Diagnostic criteria for Parkinson disease. JAMA Neurol. 1999;56:33–39.
   Google Scholar
• Jankovic J, Rajput AH, McDermott MP, et al. The evolution of diagnosis in early Parkinson disease. JAMA Neurol. 2000;57:369–372.
   Google Scholar
• Mazzotti E, Sebastiani C, Marchetti P. Patient perception of disease control and psychological distress. Cancer Manag Res. 2012;4:335–340.
   PubMedGoogle Scholar
• Verbrugghe M, Verhaeghe S, Lauwaert K, et al. Determinants and associated factors influencing medication adherence and persistence to oral anticancer drugs: a systematic review. Cancer Treatment Rev. 2013;39(6):610–621.
   PubMed Web of Science ®Google Scholar
• Amalberti R, Hourlier S. Handbook of human factors and ergonomics in health care and patient safety. In Carayon P, Ed. Human error reduction strategies in health care. Boca-Raton (FL): CRC Press; 2012. ISBN 978-1-4398-3033.
   Google Scholar
• Işıklar G, Büyüközkan G. Using a multi-criteria decision making approach to evaluate mobile phone alternatives. Comput Stand Interfaces. 2007;29(2):265–274.
   Web of Science ®Google Scholar
• Routledge PA, O’Mahony MS, Woodhouse KW. Adverse drug reactions in the elderly patients. Br J Clin Pharmacol. 2003;57(2):121–126.
   Web of Science ®Google Scholar
• Primohamed M, Sally J, Meakin S, et al. Adverse drug reactions as cause of admission to hospital: prospective analysis of 18 820 patients. Bmj. 2004;329:15–19.
   PubMedGoogle Scholar
• Kronish IM, Woodward M, Sergie Z, et al. Meta-analysis: impact of drug class on adherence to antihypertensives. Circulation. 2011;123(15):1611–1621.
   PubMed Web of Science ®Google Scholar
• Kassam R, Collins JB, Berkowitz J. Comparison of patients’ expectations and experiences at traditional pharmacies and pharmacies offering enhanced advanced pharmacy practice experiences. Am J Pharm Educ. 2010;74(5):90.
   PubMed Web of Science ®Google Scholar
• Charlesworth CJ, Smit E, Lee DS, et al. Polypharmacy among adults aged 65 years and older in the United States: 1988-2010. J Gerontol A Biol Sci Med Sci. 2015;70(8):989–995.
   PubMed Web of Science ®Google Scholar
• Mukete BN, Ferdinand KC. Polypharmacy in older adults with hypertension: a comprehensive review. J Clin Hypertens. 2016;18(1):10–18.
   PubMed Web of Science ®Google Scholar
• Tirfiro G, Spina E. Age-related changes in pharmacodynamics: focus on drugs acting on central nervous and cardiovascular systems. Curr Drug Metabol. 2011;12:611–620.
   PubMed Web of Science ®Google Scholar
• Corsonello A, Pedone C, Incalzi RA. Age-related pharmacokinetic and pharmacodynamic changes and related risk of adverse drug reactions. Curr Med Chem. 2010;17(6):571–584.
   PubMed Web of Science ®Google Scholar
• Goldberg RM, Mabee J, Chan L, et al. Drug-drug and drug-disease interactions in the ED: analysis of a high-risk population. Am J Emerg Med. 1996;14(5):447–450.
   PubMed Web of Science ®Google Scholar
• Dumbreck S, Flynn A, Nairn M, et al. Drug-disease and drug-drug interactions: systematic examination of recommendations in 12 UK national clinical guidelines. Bmj. 2015;350:h949.
   PubMed Web of Science ®Google Scholar
• Carey RM, Whelton PK. Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults: synopsis of the 2017 American College of Cardiology/American Heart Association Hypertension Guideline. Ann Intern Med. 2018;168(5):351–358.
   PubMed Web of Science ®Google Scholar
• Shippee ND, Shah ND, May CR, et al. Cummulative complexity: a functional, patient-centered model of patient complexity can improve research and practice. J Clin Epidemiol. 2012;65:1041–1051.
   PubMed Web of Science ®Google Scholar
• Ahmed S, Berzon RA, Revicki DA, et al. The use of patient-reported outcomes (PRO) within comparative effectiveness research: implications for clinical practice and health care policy. Med Care. 2012;50(12):1060–1070.
   PubMed Web of Science ®Google Scholar
• Varelius J. Health and autonomy. Med Health Care Philosophy. 2005;8:221–230.
   PubMedGoogle Scholar
• Stegemann S. Developing drug products in an aging society - from concept to prescribing In: Stegemann S, Ed. The Expectation to Treatment Model: a framework for adherence and effectiveness. AAPS Advances in the Pharmaceutical Sciences, Series 24. Heidelberg, (Germany); Springer; 2016. p.153–170. ISBN 978-3-319-43099-7.
   Google Scholar
• Manary MP, Boulding W, Staelin R, et al. The patient experience and health outcomes. N Engl J Med. 2013;368:201–203.
   PubMed Web of Science ®Google Scholar
• Stegemann S, Baeyens J-P, Becker R, et al. Design of pharmaceutical products to meet future patient needs requires modification of current development paradigms and business models. Z Gerontol Geriat. 2014;47:285–287.
   PubMed Web of Science ®Google Scholar
• Story MF. Maximizing Usability: the Principles of Universal Design. Assistive Technol. 1998;10(1):4–12.
   PubMed Web of Science ®Google Scholar
• Story MF. The principles of universal design In: Preiser WFE, Smith KH, Eds. Universal Design Handbook. 2nd. Chapter 4. New York (USA); McGraw Hill; 2011.
   Google Scholar
• van Riet-Nales DA, De Jager KE, Schobben AFAM, et al. The availability and age-appropriateness of medicines authorized for children in the Netherlands. Br J Clin Pharmacol. 2011;72:465–473.
   PubMed Web of Science ®Google Scholar
• Messina R, Becker R, van Riet-Nales DA, et al. Results from a preliminary review of scientific evidence for appropriateness of preparations, dosage forms and other product design elements for older adult patients. Int J Pharm. 2015;478:822–828.
   PubMed Web of Science ®Google Scholar
• Drumond N, van Riet-Nales DA, Karapinar-Çarkit F, et al. Patients’ appropriateness, acceptability, usability and preferences for pharmaceutical preparations: results from a literature review on clinical evidence. Int J Pharm. 2017;521:294–305.
   PubMedGoogle Scholar
• Stegemann S, Ternik RL, Onder G, et al. Defining patient centric pharmaceutical drug product design. Aaps J. 2016;18(5):1047–1055.
   PubMed Web of Science ®Google Scholar
• Reddy P, Martinez-Martin P, Brown RG, et al. Perceptions of symptoms and expectations of advanced therapy for Parkinson’s disease: preliminary report of a Patient-Reported Outcome tool for Advanced Parkinson’s disease (PRO-APD). Health Qual Life Outcomes. 2014;12:11.
   PubMed Web of Science ®Google Scholar
• Klingmann V. Acceptability of mini-tablets in young children: results from three prospective cross-over studies. AAPS PharmSciTech. 2016;18(2):263–266.
   PubMed Web of Science ®Google Scholar
• Ehrlich PR. 1968. The population bomb. New York: Riverside Press. ISBN 0-89190-867-7.
   Google Scholar